✨ Your Portfolio is fetched and updated from zerodha.
Nano Asset Management

Amerise Biosciences Ltd.

AMERISE

Get real time AI alerts about this company on your WhatsApp!
Market Cap
₹5 Cr.
P/E
94.38

Amerise Biosciences Ltd.

  • Amerise Biosciences
  • Wagend Infra Venture
  • Global Securities
FAQs on Amerise Biosciences Ltd. Shareprice

Amerise Biosciences has given lower returns compared to its competitors.
Amerise Biosciences has grown at ~-12.5% over the last 1yrs while peers have grown at a median rate of 0.0%

Yes, Amerise Biosciences is expensive.
Latest PE of Amerise Biosciences is 94.38, while 3 year average PE is 7.59.
Also latest EV/EBITDA of Amerise Biosciences is 101 while 3yr average is 62.58.

View FAQ's On Business
Growth Table
  • Amerise Biosciences Ltd.
  • Wagend Infra Venture
  • Global Securities
Balance Sheet
  • Amerise Biosciences Ltd.
  • Wagend Infra Venture
  • Global Securities
Balance Sheet Snapshot
No data available.
Fund Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end
Profit & Loss
  • Amerise Biosciences Ltd.
  • Wagend Infra Venture
  • Global Securities
Cash Flow
  • Amerise Biosciences Ltd.
  • Wagend Infra Venture
  • Global Securities
Cash Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
Ratios
= Dominant Factor
  • Amerise Biosciences Ltd.
  • Wagend Infra Venture
  • Global Securities
Quarterly Results
  • Amerise Biosciences Ltd.
  • Wagend Infra Venture
  • Global Securities
Reverse DCF
locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Raphson method.
Learn how to use Reverse DCF
FAQs on Amerise Biosciences Ltd. Financials

Amerise Biosciences balance sheet is weak and might have solvency issues

Yes, The net debt of Amerise Biosciences is increasing.
Latest net debt of Amerise Biosciences is -₹0.02 Crs as of Mar-25.
This is greater than Mar-24 when it was -₹0.03 Crs.

No, profit is decreasing.
The profit of Amerise Biosciences is -₹0.15 Crs for Mar 2024, -₹0.12 Crs for Mar 2023 and ₹0.55 Crs for Mar 2022

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Amerise Biosciences latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%

Companies resources are allocated to majorly productive assets like Plant & Machinery and unproductive assets like Cash & Short Term Investments, Capital Work in Progress, Inventory, Accounts Receivable, Short Term Loans & Advances

View FAQ's On Shareholding
Ideas Dashboard
Timeline
Watchlist
Portfolio
Alerts
Research
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech